Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login


The Cancer Letter Inc.
PO Box 9905
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Nov 30, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

ICT-107 Boosts Overall Survival by 10 Percent In Phase II Glioblastoma Trial


Updated overall survival results and immune response data a phase II trial of ICT-107 in patients with newly diagnosed glioblastoma demonstrated a survival advantage compared to the control group.

ICT-107, developed by ImmunoCellular Therapeutics Ltd., is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. The study data also show a significant association between immune response and survival, especially in HLA-A2 positive patients, the target patient population for a phase III registration trial.

The data were presented at the annual Scientific Meeting and Education Day of the Society for Neuro-Oncology in San Antonio.

To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.